Genomic Databases and Biobanks in Denmark

Area of Science:

• Bioethics
• Genomic Medicine
• Health Law

Background:

• Biobanking in Denmark is governed by a complex web of laws, including patients' rights, data protection, and research ethics reviews.
• Danish law classifies tissue samples as personal data, subjecting them to various regulations based on collection circumstances.
• A notable disparity exists in the regulation of biobank samples versus whole genome sequencing (WGS) data.

Purpose of the Study:

• To analyze the current regulatory landscape of biobanking in Denmark.
• To identify inconsistencies and potential areas for improvement in the legal framework governing biobank research.
• To examine the differential treatment of tissue samples and WGS data.

Main Methods:

• Review of existing Danish legislation pertaining to patient rights, data protection, and research ethics.
• Comparative analysis of regulatory requirements for biobank samples and WGS data.
• Examination of ethical considerations, particularly concerning patient autonomy and consent.

Main Results:

• Tissue samples are subject to a multi-layered regulatory approach, including ethics review, data protection, and patient rights.
• Information derived from WGS is regulated solely under data protection laws, despite its sensitive nature.
• Biobanks established for unspecified future research bypass research ethics review, and patient-collected samples are treated differently than those from research participants.

Conclusions:

• The current regulatory framework for biobanking in Denmark is fragmented and presents inconsistencies.
• The differing treatment of tissue samples and WGS data, as well as variations in consent requirements, warrants re-evaluation.
• Increased national attention on biobank-based research may foster a more unified and coherent regulatory approach.